Monthly Immunotherapy Expanded Approvals Update
Oct 21, 2020•15 min
Episode description
Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.
For the best experience, listen in Metacast app for iOS or Android
